OCT 06, 2016 12:00 PM PDT

The Clinical and Economic Impact of Precision Cancer Medicine

  • Executive Director of Precision Medicine & Precision Genomics, Intermountain Healthcare
      Dr. Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare, an integrated healthcare system located in the Intermountain West. Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he is still part of the research faculty focusing on cancer genomics and personalized cancer medicine. Dr. Nadauld oversees the clinical implementation of genomics cancer medicine across Intermountain Healthcare's 22 hospitals and 180 physician clinics. In his spare time Dr. Nadauld enjoys attending his children's sporting events, water sports, fishing and athletics.


    Precision medicine is a rapidly evolving paradigm powered by emerging technological, diagnostic, and pharmacological capabilities.  The clinical application of precision medicine holds promise across medical disciplines, and has become increasingly prominent in advanced cancer patients where genomic analyses can readily identify actionable somatic variants.  In spite of the clinical potential of precision cancer medicine, widespread implementation has been limited, largely due to the paucity of robust clinical experience in the space.  Leveraging the unique aspects of a large, integrated health delivery network, we have clinically implemented a comprehensive precision medicine program for advanced cancer patients.  We outline the Precision Cancer Genomics Program at Intermountain Healthcare, and provide insights into the successes, challenges and economic impact associated with the de novo implementation of an enterprise-wide precision medicine program.

    Show Resources
    Show Resources